Compare Moderna, Inc. (MRNA) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Msci Inc — how do they compare? Moderna, Inc. trades at $59.78 (market cap $23.60B), while Msci Inc trades at $561.5 (market cap $45.51B). The key difference: Msci Inc is the larger of the two by market cap, and Msci Inc pays a 1.31% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | MSCI | |
|---|---|---|
Market Cap | $23.60B | $45.51B |
Sector | Health | Financials |
52-Week High | $81.80 | $643.83 |
52-Week Low | $22.36 | $511.84 |
Enterprise Value | $19.70B | $51.67B |
Dividend Yield | — | 1.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
MSCI is trading at $561.74, down 10.64% today, but maintains strong fundamentals with consistent earnings beats and robust profitability. The company reported Q2 2026 EPS of $4.94, exceeding estimates of $4.90, driven by recurring subscription growth and ETF-linked AUM. Technical indicators show a bullish trend with key support at $606, while valuation ratios remain elevated with a P/E of 35.7. Recent strategic partnerships with UBS and the acquisition of First Street enhance its private markets and climate risk capabilities.
Outlook remains positive with 73% analyst buy ratings and a $725.44 consensus price target, implying 29% upside. Risks include high debt levels ($4.51B) and competitive pressures in financial data services. The stock offers growth potential through innovation and market expansion, but investors should monitor execution on strategic initiatives and margin sustainability amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
